Edition:
United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

3.25USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$3.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
30,849
52-wk High
$12.40
52-wk Low
$2.52

Select another date:

Thu, Dec 7 2017

BRIEF-Heat Biologics Says Receives FDA Guidance At Type C Meeting For HS-110 Clinical Trial

* SAYS RECEIVES FDA GUIDANCE AT TYPE C MEETING FOR HS-110 CLINICAL TRIAL

BRIEF-Heat Biologics reports Q3 net loss attributable to Heat $0.06 per basic and diluted share‍​

* Heat Biologics Inc - qtrly net loss attributable to Heat for the third quarter of 2017 was $0.06 per basic and diluted share‍​

BRIEF-Heat Biologics Inc files for mixed shelf of up to $50 million ‍​

* Heat Biologics Inc files for mixed shelf of up to $50 million – SEC filing ‍​ Source text - (http://bit.ly/2ltFdsE) Further company coverage:

BRIEF-Heat Biologics sets subscription price of $0.62/shr for its intended rights offering to certain existing security holders

* Says subscription price of $0.62 per share for its intended rights offering to certain of co's existing security holders - SEC filing​ Source text for Eikon: (http://bit.ly/2wZmeaM) Further company coverage:

BRIEF-Heat Biologics been granted type C meeting with FDA

* Heat Biologics- ‍been granted type C meeting with FDA; to discuss registrational pathway for non-small cell lung cancer trial with HS-110 in combination with Bristol Myers' opdivo Source text: (http://bit.ly/2wY2UeW) Further company coverage:

Select another date: